^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCR7 (Chemokine (C-C motif) receptor 7)

    i
    Other names: CCR7, BLR2, CD197, CDw197, CMKBR7, EBI1, Chemokine (C-C motif) receptor 7
    1d
    Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer. (PubMed, Br J Cancer)
    PDPN is a tumour cell-associated biomarker of plasticity in TNBC, revealing synergy between hypoxia-induced mesenchymal phenotypic shifts and CCR7 in promoting lymphatic dissemination and poor prognosis.
    Journal
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    3d
    CD8+ TEMRA cells: A double-edged sword in immunity and disease-Mechanisms and therapeutic targets. (PubMed, Int Immunopharmacol)
    Furthermore, we address the "tumor immunity paradox" by discussing the confounding role of bystander virus-specific cells and the predictive value of specific subsets (e.g., CX3CR1+ TEMRA). Finally, we highlight the potential of targeting metabolic checkpoints and senescence pathways as novel therapeutic strategies to modulate TEMRA function in clinical settings.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • CCR7 (Chemokine (C-C motif) receptor 7) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    9d
    Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma. (PubMed, Haematologica)
    Both BCMA and CD307e were more highly expressed on BM plasma-cells than CTPCs. This study is among the first to provide a comprehensive phenotypic characterisation of CD56+ CTPCs across the MM spectrum, including checkpoint and chemokine receptors, treated disease cases, and paired BM samples for NDMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR6 (C-C Motif Chemokine Receptor 6) • HLA-C (Major Histocompatibility Complex, Class I, C) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    14d
    The Lymphatic-Bone Axis in Cancer Metastasis. (PubMed, Cancers (Basel))
    Finally, we consider translational implications, highlighting why bone-targeted agents alone may prove insufficient once cells are conditioned within lymphatic niches. By mechanistically linking lymphatic priming to skeletal colonization, this review informs the rational design of multimodal therapeutic approaches that jointly target lymphatic transit and the bone microenvironment.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR7 (Chemokine (C-C motif) receptor 7)
    14d
    Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma. (PubMed, Hepatol Commun)
    The TLSRS shows a correlation with both prognosis and immunotherapy response in patients with HCC, suggesting its potential value in advancing precision medicine for HCC.
    Journal • Gene Signature • IO biomarker
    |
    IL7R (Interleukin 7 Receptor) • CCR7 (Chemokine (C-C motif) receptor 7) • ACKR1 (Atypical Chemokine Receptor 1)
    15d
    β‑Arrestin-Mediated Activation of Chemokine Receptor CCR7 by Human β‑Defensin‑3 Drives Oral Squamous Cell Carcinoma Progression. (PubMed, JACS Au)
    Moreover, distinct phosphorylation signatures within the serine/threonine clusters of the C-terminal tail of CCR7 were found to govern downstream signaling outcomes. Collectively, these results reveal a mechanism reliant on both disulfide bond stability and phosphorylation patterns through which hBD3 differentially regulates CCR7 function, providing novel insights into ligand-specific receptor modulation and potential therapeutic strategies for CCR7-mediated malignancies.
    Journal
    |
    CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21) • ARRB1 (Arrestin Beta 1)
    15d
    FKBP5 isoforms shape immune pathways related to tumor tolerance. (PubMed, Cell Death Discov)
    These findings support the conclusion that inhibiting FKBP51 splicing preserves lymphocyte effector activity and prevents their transition toward resting or exhausted states. In the tumor context, this translates into a heightened antitumor immune response and a reduction in tumor tolerance.
    Journal
    |
    BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCR7 (Chemokine (C-C motif) receptor 7) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • FKBP5 (FKBP Prolyl Isomerase 5) • GSDME (Gasdermin E)
    16d
    Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis. (PubMed, Front Immunol)
    Notably, cytokine signatures in peripheral blood are emerging as prognostic biomarkers and predictive indicators for immune checkpoint blockade efficacy, particularly PD-1 inhibitors. This review systematically summarizes the current understanding of soluble mediator-driven mechanisms in NSCLC progression, including cytokines and chemokines, providing new opportunities for biomarker-guided precision therapy and combination strategies in NSCLC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21)
    24d
    Association of CCL21+ CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
    Clinically, higher CCL21 expression, elevated CCL21+ CAF signature scores, and stronger CCL21-CCR7 signatures in B cells were associated with favourable outcomes. Together, these data suggest that CCL21+ CAFs or CCL21 are potential prognostic biomarkers for risk stratification and immune microenvironment profiling and highlight the CCL21-CCR7 axis as a candidate pathway for therapeutic modulation of TLS maturity in PSCC.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • ACTA2 (Actin Alpha 2 Smooth Muscle) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21)
    1m
    APC-targeted DNA vaccines: the role of CCL19 in immune cell recruitment and early onset of the immune response. (PubMed, Cancer Immunol Immunother)
    CCL19 serves as an effective APC-targeting unit when fused to neoantigens, maintaining chemotactic and signaling properties that improve DNA vaccine immunogenicity and tumor control. This chemokine-mediated strategy offers a flexible approach to increase DNA vaccine potency with broad potential applications in cancer immunotherapies and beyond.
    Journal • IO biomarker
    |
    CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7)
    1m
    Spatial profiling uncovers multicellular dynamics in early relapse of hepatitis B virus-associated follicular lymphoma. (PubMed, Commun Biol)
    Except for virus-induced immune exhaustion, distinct contributions to POD24 occurrence from malignant cells and immunosuppressive cell communities under distinct HBV infection states are discerned such as through CCL21/CCR7 signaling pathway. Taken together, our spatial multicellular dynamics reveal an increased prevalence of MBLM and variable FDC phenotypes which is associated with POD24 occurrence in HBV-related FL tumors.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21) • PTPRCAP (Protein Tyrosine Phosphatase Receptor Type C Associated Protein)